Dr. Marc Hedrick
Good Jonathan. provide you we for everyone. you, XXXX results. of overview recent joining Thank and afternoon, today second discuss financial again our us Thank it. Appreciate as an once business highlights quarter
Sims, Chief a XXXX the of our on Dr. shaping development. such fronts. pleased very today Chief question-and-answer year XXXRNL Medical begin Officer; about I'll call critical LaFrance I Andrew performance be leptomeningeal of clinical across recent progress reviewing our say an clinical excited me Joining Also, continue before call Norman amount the and a in for review and to drug to period. with could will to turning our And is outstanding performance up Andrew metastases. tremendous all and our indications, our and by Dr. Officer. joining Financial be the for with LaFrance, call to Plus the financials. two clinical over corporate be drug very active manufacture our Therapeutics team's glioblastoma I certainty progress in of I'm that our as is areas us
its very safety with clinical a of solid functioning While with response. consistent a design showing mid-stage that the development, XXXRNL biologic is still is to coupled early- in biologically in objectives profile manner a original and
In July Piramal drug the of Company NanoLiposome Pharma Development of the with Program XXXRNL So specifically technology Solutions. cGMP let's CMC initiation completed and Rhenium-XXX the start activities. manufacturing our XXXX, intermediate transfer and with
even manufacture product in and nanoliposomal believe testing, late-stage of FDA Additionally, drug for guidance it to the clinical we for trials products be commercialization. in compliant with use intermediate and drug stability
the targets. X time in planned for to expect on in with recurrent second XXXX In opinion summary of disease Phase seek drug public have clinical development their a submitted those Company ongoing the adults a when making We the meeting trials plans briefing glioblastoma metastases of package to finalized. XXXRNL half QX, Company and minutes sufficiency GMP in FDA future CMC anticipates for the leptomeningeal drug of GMP manufacturer. the to availability The all on
Regarding In Medicine in trial XXXRNL lead the the of Institute. funded recurrent the our U.S. Annual NIH positive for multi-center patients GBM. a for and dual interim presented is sequential it's and on currently, recurrent investigational with open at National volume program, XXXX, Society Imaging data Nuclear GBM significant is trial label this for trial to Phase the The the Meeting, by and X/X cohort drug dose July Bill currently escalation degree Cancer and a Dr. Molecular enrolling Phillips study glioblastoma. ReSPECT-GBM
patients been During after the signals cohorts patients XX there adult dose radiation of an and administration, with of been greater has have recurrent single date, presentation, To a in toxicities seven average Company XXX the noted have across receiving Gy. increasing evaluated dose. that of no efficacy trial observed promising GBM dose-limiting than the absorbed
versus survival. weeks median recent similar compares a is overall website. monotherapy weeks of data XXX favorably As of was data improvement detail about patients XX survival greater greater two-year patients, less a XXX this real-world overall recent -- in than Furthermore, and presented that the those median the XXX patients data referenced XXX with our meta-analysis XX in QX, survival the in in than subset median most receiving than Gy receiving And in in bevacizumab, overall shows Gy. receiving of Gy on
a first observed for far is XXXRNL Based formal as submitted for forward detailed signals Big a agency's in purpose promising for and of clinical believe medical opinion the steps combination From minutes Company's we would the delivery the FDA methodology. we and finalized. efficacy we of picture, making Company the drug intend the to this, for ongoing clinical and development on development. safety clinical approach. mid-XXXX. best on summary well to a This development the what best what novel defining at longer-term to least the in-license new determine public correspondence and based approval path like radiopharmaceutical incorporate a agency novel thus second far, planned, clinical a a three-pronged interaction next plan of positive of of with craft As plan is leading collaborative briefing potential unique a a anticipates in The those since the package data the need, very the we'd is profile thus meeting to observed RNL the when poorly overall met very bevacizumab.
observe to First, work to and to and explore have the dose-limiting continue to the dose continue current trial Phase further we also escalation yet X/X further dosing delivery parameters. toxicities as to optimize
to morphologic to to significant those with completely Second, And administration. in they be the to extension may if or tumor in if were the recur, dosing. serial go intend incompletely is geometric potentially areas Company This single single allowed with we again, multi-dose treat trial that QX, of proceed treat either going key a treated or FDA to the administration. larger or us a to explore to complexity a in after difficult allow tumors tumors
our in combination the and Phase full sponsored mentioned a a today the provide back or X dream, combined Andrew Dr. needed our disease their will volume big a fill the dose a fall, managed or as throughout treat begin discussions as trial going with the cancer a treatments medium-sized explore Company each which chronic Taking X Medical Phase presentation. We appropriate is to install exact brain likely patient RNL that's we ReSPECT-GBM from us the forward by dose picture, for by NIH-sponsored step the Society cohort move Oncology patients current Brenner, X/X design serial FDA. the in transform be the be this but ongoing, and allows to to that at trial on don't big a of for up whether will trial's in that sentence data investigator, just in have of This I Phase putting studies to to time, with to the X September European is principal be XX. that's small- Finally, to podium date to Phase to disease Paris, death recommended course. X to trial is Phase X/X France, a and will tumors, that's update
X, end-stage or efficacy as standard fluid weeks. common patient trial, dose which without dose board is three two-year most tumor The you, X% tolerated plan caused X/X which Cohort X%, reminder, dose-limiting tumor leptomeningeal in of assay and remind about its cerebrospinal delivered structures a ReSPECT-LM a an six monitoring multicenter the system entered the treatment Inc. escalation actually provides longer survival and the about rates is tolerate -- growing away. approved as trial affected therapy of given highly initial eight to Biocept therapies and of XXXRNL can metastases move administered external tumors LM X to LM. the To burden line we're has specific of to the had quantify LM independent QX, to In the The fatal with look survival by orally, to and intravenously development in into weekly things leptomeninges. the trial or in us cell of includes Also determine LM, safety completed survival better and treatment the Cohort primary a giving typically is agreement ReSPECT current on directly Biocept's to complication space the until the allows aggressive assess with can median therapy also and is time escalation about twice rise doing. sensitive or months, LM As fluid central successfully that ahead fluid the grab be melanoma. There assay The and indicators no and that or four with treatment on sites, in toxicities at to are LN this employ with damage. program, LM to markers one- cell data system the nervous incidence of such method the LM QX, is without XXXRNL. we to potentially cerebral radiation safety care, dose, the system in respectively, of local a associated maximum cancers that central and and tumor Company LM. are our process nervous to was the trial. XXXRNL depending commonly study of advanced Company the a radiation beam enrollment infiltrate into malignancies cohort this spinal X/X passes ReSPECT of gastrointestinal Phase bag no chemotherapy in followed with announced cancer in Phase of multiyear approved
the be enrolled will the or evaluate determination in and ultimately, results biologic cadence Assay treatment patients used retreatment trial. to treatment and potential to of in of response timing efficacy the
we're the radio track certain in-licensed studies CMC track for on BAM, technology activities the we transfer and that. embolic to recently just and year, called key are novel, completed of our complete end regarding preclinical BAM and have on technology or Finally, phase by the microparticle feasibility XXXRNL IND-enabling
In that circulating technology means solid the we with cancer, embolic focus a permanent. we are having human there existing bioresorbable has they're a body. or meet potent Biodegradable the organs Alginate of the believe liver that NanoLiposome year technology of which tumor fully decades the technology, of the other with non-operable this harm is to bioresorbable, about for addition, almost many is well. vascular Microspheres we only tumor there the organ radiotherapeutic treatment the a survival cancer. radiologic are resorbable therapeutic many could systemic body of the out planning selectively in this initially solves technology problems breadth as using of out that's and developing With resorbable incur drugs system next-generation radio to that FDA the liver for And a any a rate next-generation highly standard without to as marrow biomaterial meeting radioembolization interventional current pre-IND for with been radio are only very to therapy not leverage plan embark the five-year for target bone a and BAM reach can our low isotope, the coupled XX% Rhenium-XXX
Andrew, with the CFO, I'll will So the over financials. floor Andrew? who that, our to turn review
